4//SEC Filing
Postma Robert W 4
Accession 0000950170-25-090587
CIK 0001107421other
Filed
Jun 25, 8:00 PM ET
Accepted
Jun 26, 9:19 PM ET
Size
12.7 KB
Accession
0000950170-25-090587
Insider Transaction Report
Form 4
Postma Robert W
Director
Transactions
- Purchase
Series A-1 Convertible Preferred Stock
2025-04-11$2.76/sh+500$1,380→ 500 total(indirect: By WaterMill Asset Management Corp.)Exercise: $2.76From: 2025-04-11→ Common Stock (181,159 underlying) - Award
Common Stock
2025-04-13$2.92/sh+20,804$60,748→ 29,083 total - Purchase
Series A-2 Convertible Preferred Stock
2025-06-24$4.49/sh+600$2,694→ 600 total(indirect: By Watermill Asset Management Corp)Exercise: $4.49From: 2025-06-24→ Common Stock (133,630.29 underlying)
Holdings
- 33,333(indirect: By WaterMill Asset Management Corp.)
Common Stock
- 24(indirect: By Spouse)
Common Stock
- 3,737
Employee Stock Option (right to buy)
Exercise: $10.30Exp: 2034-06-05→ Common Stock (3,737 underlying)
Footnotes (4)
- [F1]The shares are directly held by WaterMill Asset Management Corp. ("WaterMill"). The Reporting Person serves as the principal of WaterMill.
- [F2]The preferred stock is perpetual and therefore has no expiration date.
- [F3]The reporting person disclaims beneficial ownership of these equity securities to the extent that after giving effect of the conversion of the preferred stock and the underlying common stock issuance, the reporting person would beneficially own in the aggregate in excess of 4.99% of the outstanding shares immediately after giving effect to such conversion or issuance.
- [F4]One-twelfth of the Option vests each month on the monthly anniversary of June 6, 2024, with any amount that remains unvested on the date immediately preceding the Company's 2025 annual general meeting of stockholders vesting thereon.
Documents
Issuer
Alaunos Therapeutics, Inc.
CIK 0001107421
Entity typeother
Related Parties
1- filerCIK 0001827847
Filing Metadata
- Form type
- 4
- Filed
- Jun 25, 8:00 PM ET
- Accepted
- Jun 26, 9:19 PM ET
- Size
- 12.7 KB